CNS Pharmaceuticals, a Houston-based clinical pharmaceutical firm, is focused on the development of novel anti-cancer drug candidates targeting central nervous system tumors. Their lead candidate, Berubicin, has successfully completed Phase I clinical trials and is designed for the treatment of glioblastoma multiforme. CNS has struck license agreements with Houston Pharmaceuticals and The University of Texas M.D. Anderson Cancer Center, alongside a development agreement with WPD Pharmaceuticals Inc. Founded in 2017, the company is committed to the advancement of cancer care through cutting-edge pharmaceutical solutions.